GlassScriptPhysician profile
Navya M Reddy
NPI 1083069611
$3,099.91
in general payments reported to CMS, 2019-2025
18 companies · $696 in 2025
The $696 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $167 · 2022: $934 · 2023: $506 · 2024: $797 · 2025: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,997 · Travel and Lodging: $1.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,997.19 |
| Travel and Lodging | $1.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $717.03 | 2024-2025 | Tepezza, Evenity |
| Lilly USA, LLC | $456.06 | 2022-2024 | Zepbound, Mounjaro, Jardiance |
| Dexcom, INC. | $320.10 | 2022-2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $294.11 | 2022-2024 | |
| Abbott Laboratories | $237.41 | 2022 | |
| Pfizer INC. | $206.67 | 2025 | |
| Horizon Therapeutics Plc | $149.91 | 2022 | |
| Stryker Corporation | $145.50 | 2024 | Insignia |
| Bayer Healthcare Pharmaceuticals INC. | $123.91 | 2024 | |
| Si-Bone, INC. | $121.13 | 2021 | |
| Ascensia Diabetes Care US INC. | $100.80 | 2023 | |
| Tandem Diabetes Care, INC. | $85.59 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals LP | $29.11 | 2021-2022 | |
| Beta Bionics, INC. | $28.92 | 2023 | Ilet Bionic Pancreas |
| Ascendis Pharma Endocrinology INC | $28.55 | 2025 | Yorvipath |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $26.65 | 2024 | Minimed 780g |
| Rhythm Pharmaceuticals, INC. | $16.60 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Navya Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.